Prevalence of cigarette smoking among opioid-dependent individuals is 6-fold that of the general U.S. adult population and their quit rates are notoriously poor. One possible reason for the modest cessation outcomes in opioid-dependent smokers may be that they experience more severe tobacco withdrawal upon quitting. In this secondary analysis, we evaluated tobacco withdrawal in opioid-dependent (OD) smokers versus smokers without co-occurring substance use disorders (SUDs). Participants were 47 methadone-or buprenorphine-maintained smokers and 25 non-SUD smokers who completed 1 of several 2-week studies involving daily visits for biochemical monitoring, delivery of financial incentives contingent on smoking abstinence, and assessment of withdrawal via the Minnesota Nicotine Withdrawal Scale (MNWS). Prior to quitting smoking, OD smokers presented with higher baseline withdrawal scores than non-SUD smokers (1.7 Ϯ 0.2 vs. 0.7 Ϯ 0.2, respectively; F[1, 63] ϭ 7.31, p Ͻ .001). Withdrawal scores in both groups decreased over the subsequent 2-week period with no group differences, F(1, 910) ϭ 0.50, p ϭ .48. A similar pattern was observed on craving (i.e., Desire to Smoke item of MNWS), although the trajectory of decrease over time on this item was also moderated by gender. Overall, there was no difference in withdrawal during biochemically verified smoking abstinence between OD and non-SUD smokers, suggesting that elevated withdrawal severity following quitting may not be a major factor contributing to the poor cessation outcomes consistently observed among OD smokers. Further scientific efforts are needed to improve our understanding of the high smoking rates and modest cessation outcomes in this challenging population.
Cigarette smoking is the leading preventable cause of morbidity and mortality in the United States (U.S. Department of Health and Human Service, 2014) . Whereas smoking has steadily declined in the general population, it remains entrenched among certain vulnerable populations. Individuals with substance use disorders, in particular, are overrepresented among current cigarette smokers and bear a disproportionate burden of smoking-related disease and premature death. This is especially the case among individuals with opioid-dependent, in whom prevalence of smoking is 6-fold that of the general U.S. adult population (84 -94% vs. 15%, respectively; Guydish et al., 2011 Guydish et al., , 2016 Jamal et al., 2016; Nahvi, Richter, Li, Modali, & Arnsten, 2006; Richter, Gibson, Ahluwalia, & Schmelzle, 2001 ). Furthermore, their responses to smoking cessation treatments are notoriously poor, with quit rates one fourth that of smokers without substance use disorders (Miller & Sigmon, 2015; Okoli et al., 2010; Zirakzadeh, Shuman, Stauter, Hays, & Ebbert, 2013) .
One potential reason for the modest cessation outcomes in opioid-dependent smokers is that this group may experience more severe tobacco withdrawal upon quitting (Miller & Sigmon, 2015; Story & Stark, 1991) . However, whereas prior studies have found that smokers with current or past alcohol dependence report more severe tobacco withdrawal when they stop smoking (Hughes, 1996) , the limited data on tobacco withdrawal in opioid-dependent smokers thus far have been mixed, with one study demonstrating that methadone attenuates tobacco withdrawal (Elkader, Brands, Selby, & Sproule, 2009 ) and another showing increases in withdrawal during methadone dose increases (Story & Stark, 1991) . To our knowledge, no prior studies have examined the effects of buprenorphine on tobacco withdrawal.
In the present secondary analysis, we sought to evaluate tobacco withdrawal in opioid-dependent (OD) smokers versus smokers without comorbid substance use disorders (SUDs) using data from five outpatient laboratory studies that were conducted at the University of Vermont by our research group and utilized a uniform platform of daily visits involving biochemical monitoring, assessment of withdrawal, and delivery of financial incentives contingent on smoking abstinence (Bradstreet et al., 2014; Dunn, Sigmon, Thomas, Heil, & Higgins, 2008; Dunn et al., 2010; Sigmon et al., 2015; Yoon, Higgins, Bradstreet, Badger, & Thomas, 2009 ). Also of interest was whether gender was a moderator of nicotine withdrawal, given that prior literature in the general population has suggested an association between gender and tobacco withdrawal and/or craving (e.g., Eissenberg, Adams, Riggins, & Likness, 1999; Leventhal et al., 2007; Pang & Leventhal, 2013; Piasecki, Jorenby, Smith, Fiore, & Baker, 2003; Weinberger, Platt, Shuter, & Goodwin, 2016) .
Method Participants
In the three studies examining the efficacy of voucher-based financial incentives to promote smoking abstinence in OD smokers, participants were methadone-or buprenorphine-maintained adults (Dunn et al., 2008 (Dunn et al., , 2010 Sigmon et al., 2015) . Eligible participants had to be 18 -65 years old, report smoking Ն10 cigarettes per day for Ն1 year, be on a stable methadone or buprenorphine dose, and have Յ30% samples testing positive for illicit drugs. Participants who were pregnant or presented with active serious mental or physical illness that might interfere with study participation were excluded.
The non-SUD smoker sample included participants from two studies using monetary incentives to experimentally induce smoking abstinence (Bradstreet et al., 2014; Yoon et al., 2009) . Eligible participants had to be 18 -55 years old, in good health, report smoking Ն10 cigarettes per day for Ն1 year, report no plans to quit smoking in the near future, and have an expired breath carbon monoxide (CO) sample at intake of Ն15 ppm (Bradstreet et al., 2014) or 18 ppm (Yoon et al., 2009) . Those who were pregnant, had active serious mental or physical illness, were using psychoactive medications, or had current drug or alcohol dependence other than tobacco dependence were excluded.
Procedures
In the studies with OD smokers, eligible participants were randomly assigned to a Contingent or Noncontingent experimental group and visited the laboratory daily for 14 consecutive days (Dunn et al., 2008 (Dunn et al., , 2010 Sigmon et al., 2015) . At each visit, breath CO and urine cotinine samples were collected for biochemical verification of smoking status. Contingent participants received voucher-based incentives for CO levels Յ6 ppm on Study Days 1-5 and cotinine levels Յ80 ng/ml on Days 6 -14. Noncontingent participants received vouchers independent of smoking status.
In the studies with non-SUD smokers, eligible participants were randomly assigned to a Contingent or Noncontingent experimental group and visited the laboratory daily for 14 (Yoon et al., 2009) or 15 (Bradstreet et al., 2014) consecutive days. Contingent participants received monetary incentives for CO readings of Յ4 ppm on Study Days 1-7 and cotinine levels of Յ80 ng/ml on Days 8 -14. Noncontingent participants received monetary incentives independent of smoking status.
While the present manuscript reports on the results of secondary analyses on deidentified data collapsed across five outpatient laboratory studies, those original studies have been published previously and were approved by the University of Vermont Committee on Human Research in the Medical Sciences. All participants provided written informed consent prior to participating.
Measures
Intake assessments included the Fagerstrom Test for Cigarette Dependence (FTCD; Fagerström, 2012) and the Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1998) , which measure nicotine dependence and tobacco withdrawal, respectively. The MNWS is measured on an ordinal scale: 0, none; 1, slight; 2, mild; 3, moderate; 4, severe. The seven Diagnostic and Statistical Manual of Mental Disorders, fifth edition, items from the MNWS were averaged for a single severity score (range 0 -4; Cronbach's alpha ϭ .87), with the Desire to Smoke item analyzed separately as a measure of craving (Hughes & Hatsukami, 1998) . At each subsequent visit during the 2-week studies, participants completed the MNWS and provided breath and urine samples. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Data Analyses
To prevent ongoing smoking from confounding our evaluation of tobacco withdrawal, analyses were limited to the 72 participants (47 OD and 25 non-SUD smokers) who received the abstinencecontingent interventions and provided Ͼ85% of samples indicating smoking abstinence (Dunn et al., 2010) . Complete abstinence (i.e., 100% of samples indicating smoking abstinence) was not required as prior research suggests that small amounts of smoking do not substantially influence withdrawal symptoms .
Baseline characteristics between the OD and non-SUD smoker groups were compared using 2 tests for categorical variables and t tests for continuous measures. Repeated-measures analysis of covariance using maximum likelihood estimation was used to examine mean MNWS and Desire to Smoke scores over time between the two groups. All variables that differed between the two groups at intake were included in the models as covariates (i.e., age, education, number of years smoked regularly, intake breath CO, FTCD score), as were the baseline MNWS and Desire to Smoke scores. As noted earlier, gender was also included as a moderator in subsequent analyses. Change in withdrawal during the first 24 hours of abstinence was examined by comparing the difference in mean scores from the precessation visit to the first day of abstinence (Hughes, 2007a) . Time course of withdrawal thereafter was assessed by comparing mean scores between the groups on the remaining 14 days, with time modeled as a continuous variable. Sensitivity analyses were also conducted to examine potential effects of opioid medication type (i.e., methadone, buprenorphine) on withdrawal and craving within the OD smoker group. Regarding missing data, all of the OD and non-SUD smokers included in these analyses completed the 14-day studies, and data were missing for Ͻ1% and 1.5% of the non-SUD and OD smokers, respectively. Statistical significance was determined based on ␣ ϭ .05, with all analyses performed using SAS statistical software version 9.4 (SAS Institute, Cary, NC).
Results

Participant Characteristics
Among OD smokers, 70% and 30% were enrolled in methadone (102 Ϯ 48 mg/day) or buprenorphine (13 Ϯ 5 mg/day) treatment, respectively. Relative to non-SUD smokers, the OD smokers were older (p Ͻ .05), had completed fewer years of education (p Ͻ .01), and had been smoking regularly for more years (p Ͻ .01; see Table  1 ). Although there were no group differences in baseline urinary cotinine levels or self-reported number of cigarettes smoked per day, OD smokers did present with lower CO values and FTCD scores at intake (p's Ͻ .01).
Tobacco Withdrawal
Prior to quitting smoking (i.e., at Study Intake), OD smokers presented with higher MNWS scores than non-SUD smokers (1.7 Ϯ 0.2 vs. 0.7 Ϯ 0.2, respectively; F[1, 63] ϭ 7.31, p Ͻ .001), after adjusting for the covariates in the model. Changes in withdrawal severity between Intake and the first day of abstinence (i.e., Study Day 1) did not differ by group, (F(1, 60) ϭ 3.02, p ϭ .09; Figure  1 , upper panel). Thereafter, tobacco withdrawal decreased over time in both groups, (F(1, 911) With regard to the Desire to Smoke item of the MNWS, OD smokers presented with higher scores prior to quitting smoking (i.e., at Intake) compared with non-SUD smokers (3.2 Ϯ 0.2 vs. 1.7 Ϯ 0.3, respectively; (F(1, 63) ϭ 15.97, p Ͻ .001). There was a significant group effect, (F(1, 60) ϭ 9.25, p Ͻ .01) on changes in craving between Intake and the first day of abstinence (i.e., Day 1), with OD smokers experiencing a decrease in craving of Ϫ0.61 Ϯ 0.2, (t(60) ϭ 2.52, p ϭ .01) compared with non-SUD smokers whose craving increased by 0.82 Ϯ 0.3, (t(60) ϭ Ϫ2.82, p Ͻ .01). There was also a significant gender ϫ group ϫ time interaction in craving over the remaining study visits, (F(1, 907) Within the OD smoker group, participants maintained on both medications showed a significant decrease in craving over time, with some evidence of craving decreasing at a faster rate among those maintained on methadone than buprenorphine, (F(1, 587) ϭ 7.47, p ϭ .01).
Discussion
This study provides the most rigorous evaluation of tobacco withdrawal in opioid-dependent smokers to date as well as the first comparison with a sample of smokers without comorbid SUDs.
Prior to quitting smoking, OD smokers presented with higher baseline tobacco withdrawal scores compared with non-SUD smokers, although the clinical significance of this difference (i.e., approximately one unit on a four-point ordinal scale) is unclear. While the elevated precessation withdrawal observed here is consistent with prior studies among vulnerable smokers with psychiatric or drug abuse problems (Heil, Higgins, Mongeon, Badger, & Bernstein, 2006; Madden et al., 1997; Tidey, Colby, & Xavier, 2014; Tidey, Rohsenow, Kaplan, Swift, & Adolfo, 2008) , it runs counter to some prior data suggesting that opioid agonists may attenuate tobacco withdrawal (Elkader et al., 2009; Jackson, Muldoon, De Biasi, & Damaj, 2015) . Also important to note is the possibility that methodological differences between studies may have contributed to baseline differences in withdrawal (e.g., timing of withdrawal assessment during the intake process, use of the CO-based inclusion criterion in the non-SUD studies).
Over the 2 weeks following quitting smoking, OD and non-SUD smokers showed a similar pattern of withdrawal, with scores declining in both groups in a manner that is consistent with that seen in the general population of smokers (Hughes, 2007b) . It is worth noting that OD smokers did not show the initial increase in withdrawal upon quitting that was seen in the non-SUD smoker group and is typical in smokers more generally (Hughes, 2007b) . Whether this is because their baseline withdrawal was already elevated, their opioid agonist medications attenuated further increases in withdrawal, or other factors is unknown but merits further study.
With regard to tobacco craving, the picture was more mixed with OD smokers evidencing a decrease in craving on the first day of abstinence relative to the increase seen in the non-SUD smoker group. There was also evidence that gender may play a role in craving following quitting smoking, although the effect was modest, with group differences seen only in females. This is consistent with prior studies showing generally mixed findings on gender differences in tobacco withdrawal and craving (Leventhal et al., 2007; Pang & Leventhal, 2013; Piasecki et al., 2003; Svikis, Hatsukami, Hughes, Carroll, & Pickens, 1986; Weinberger et al., 2016) .
Several strengths of the present study are worth noting. We extended upon the prior findings by Elkader et al. (2009) by examining tobacco withdrawal over a longer period of time (i.e., 14 vs. 3 days), using a slightly larger sample size of OD smokers (i.e., 47 vs. 40), and including patients maintained on buprenorphine in addition to methadone. Several limitations also should be mentioned. First, we did not assess withdrawal over several days prior to the quit attempt as has been recommended to avoid confounding due to anticipatory increases in anxiety or withdrawal (Hughes, 2007a; Shiffman, West, & Gilbert, & the SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials, 2004) . Additionally, although larger than prior studies, the sample size in the present analyses was still limited and thus could have undermined our ability to detect group differences in nicotine withdrawal. Combining multiple studies together also may have resulted in increased heterogeneity within each group, leading to a reduction in power. Finally, regarding the OD smoker group in particular, we did not control their opioid medication dose or the timing of its administration relative to study procedures. This study also did not permit us to distinguish between the effects of opioid This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
dependence per se versus opioid agonist maintenance in the OD smoker sample.
Conclusions
This secondary analysis offers the most thorough examination of tobacco withdrawal in opioid-dependent smokers to date, using smokers without comorbid SUDs as a comparison sample. Despite presenting with elevated withdrawal prior to quitting smoking, opioid-dependent smokers who successfully abstained from smoking over a 2-week period experienced a profile of withdrawal that was remarkably similar to non-SUD smokers. These data suggest that elevated withdrawal severity following quitting may not be a major factor in the poor cessation outcomes consistently observed in this group. Continued investigations are needed to improve our understanding of the high smoking rates and modest cessation outcomes in this challenging smoker population.
